1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files

 
• By Derrick Gingery

The 'technical detail' needed to be resolved in part to ensure there would be no shortages after the 2020 change from regulation as drugs to biologics for certain protein products, the agency said.

FDABldg1ExteriorWithCircle_1200x675
The FDA's proposed rule is intended to ease the burden of the 2020 biologics transition process. • Source: Shutterstock

A subset of products subject to the biologics transition process in March 2020 may continue using drug master file information after they become biologics license applications, even though the US Food and Drug Administration currently prevents the practice.

The FDA issued a proposed rule 27 June that would allow these products, which include some reproductive hormones and enzymes, to continue referencing drug substance, drug intermediate and drug product information from master files once they

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.